Descrease article font dimension
Enhance article font dimension
Shortages of Ozempic and Wegovy which have been in place for greater than two years have been resolved, as provides of the favored diabetes and weight problems remedies proceed to enhance, federal regulators mentioned Friday.
The drugmaker Novo Nordisk can meet current and future demand within the U.S., the Meals and Drug Administration mentioned. However sufferers should still see some provide disruptions because the medicines transfer from the producer to distributors after which to pharmacies.
The injectable medicine have been in scarcity since 2022.
1:27Ozempic can decrease possibilities of a number of well being situations however comes with dangers, examine finds
In December, the FDA declared that shortages of remedies Zepbound and Mounjaro from one other drugmaker, Eli Lilly and Co., additionally had been resolved. Zepbound is authorised to deal with weight problems and Mounjaro is authorised for diabetes. They use the identical energetic ingredient, tirzepatide.
Trending Now
‘I feel disrespected’: Ontario city considers eradicating U.S. flags from its buildings
Grimes pleads with Elon Musk for him to contact her over youngster’s ‘medical crisis’
Story continues under commercial
The U.S. discover of decision comes nearly two months after Canada, which had additionally been experiencing shortages of Ozempic and related weight-loss medicine, mentioned on Jan. 27 that its provide had stabilized.
Get weekly well being information
“Ozempic and Wegovy are available across Canada, and we do not anticipate any future shortages at this time,” a spokesperson for Novo Nordisk Canada mentioned in an announcement.
Ozempic, for diabetes, and Wegovy, for weight reduction, use the energetic ingredient semaglutide.
All 4 medicine are a part of a GLP-1 class of remedies that has proven unprecedented outcomes for serving to individuals shed weight by lowering urge for food and boosting emotions of fullness.
Gross sales have soared for the medicine in recent times. However the shortages have made entry to those medicine difficult for a lot of sufferers because the drugmakers have raced to extend manufacturing.
Extra on HealthMore movies
© 2025 The Canadian Press
